Difference between revisions of "Gilteritinib (Xospata)"
Jump to navigation
Jump to search
m (Jwarner moved page Gilteritinib (ASP2215) to Gilteritinib (Xospata): FDA approval) |
m |
||
| Line 6: | Line 6: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *11/28/2018: Initial FDA approval for treatment of adult patients who have relapsed or refractory [[Acute_myeloid_leukemia | + | *11/28/2018: Initial FDA approval for treatment of adult patients who have relapsed or refractory [[Acute_myeloid_leukemia|acute myeloid leukemia (AML)]] with a [[Biomarkers#FLT3|FLT3]] [[Biomarkers#Alterations|mutation]] as detected by an FDA-approved test. |
==Also known as== | ==Also known as== | ||
| Line 14: | Line 14: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| + | [[Category:Mutation-specific medications]] | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
Revision as of 16:36, 12 January 2020
Mechanism of action
Tyrosine kinase inhibitor of FLT3, AXL, and ALK
Diseases for which it is used
History of changes in FDA indication
- 11/28/2018: Initial FDA approval for treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.
Also known as
- Code name: ASP2215
- Brand name: Xospata